{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Female+Genital+Malignant+Neoplasms", "query": { "condition": "Other Female Genital Malignant Neoplasms" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 143, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Female+Genital+Malignant+Neoplasms&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T07:16:01.617Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01552434", "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Castleman Disease", "Digestive System Carcinoma", "Erdheim-Chester Disease", "Lip and Oral Cavity Carcinoma", "Lymphangioleiomyomatosis", "Malignant Endocrine Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Male Reproductive System Neoplasm", "Malignant Neoplasm", "Malignant Respiratory Tract Neoplasm", "Malignant Thoracic Neoplasm", "Malignant Urinary System Neoplasm", "Mesothelial Neoplasm", "Metastatic Malignant Neoplasm", "Metastatic Urothelial Carcinoma", "Neurofibromatosis Type 2", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Breast Carcinoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Digestive System Carcinoma", "Recurrent Female Reproductive System Carcinoma", "Recurrent Male Reproductive System Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Pharyngeal Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Malignant Neoplasm", "Soft Tissue Neoplasm", "Stage III Breast Cancer AJCC v7", "Stage III Pharyngeal Cancer", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Pharyngeal Cancer", "Stage IVA Pharyngeal Cancer", "Stage IVB Pharyngeal Cancer", "Stage IVC Pharyngeal Cancer", "Thyroid Gland Neoplasm" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 154, "start_date": "2012-10-16", "completion_date": "2026-05-08", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-07-24T07:16:01.617Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552434" }, { "nct_id": "NCT04853017", "title": "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Minimal Residual Disease", "KRAS G12D", "KRAS G12R", "NRAS G12D", "NRAS G12R", "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer", "Non-small Cell Lung Cancer", "Ovarian Cancer", "Cholangiocarcinoma", "Bile Duct Cancer", "Gallbladder Carcinoma" ], "interventions": [ { "name": "ELI-002 2P", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elicio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-10-04", "completion_date": "2024-09-24", "has_results": true, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-07-24T07:16:01.617Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04853017" }, { "nct_id": "NCT00024258", "title": "Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Liver Cancer", "Neuroblastoma", "Ovarian Cancer", "Retinoblastoma", "Sarcoma" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "40 Years", "sex": "ALL", "summary": "Up to 40 Years" }, "enrollment_count": 22, "start_date": "2001-03", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2015-11-25", "last_synced_at": "2026-07-24T07:16:01.617Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024258" }, { "nct_id": "NCT06126276", "title": "Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Female Reproductive System Neoplasm", "Malignant Solid Neoplasm", "Recurrent Malignant Female Reproductive System Neoplasm", "Recurrent Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Neratinib Maleate", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2024-05-07", "completion_date": "2027-02-20", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-07-24T07:16:01.617Z", "location_count": 187, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 149 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06126276" }, { "nct_id": "NCT00002854", "title": "High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 33, "start_date": "1994-12", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-08-26", "last_synced_at": "2026-07-24T07:16:01.617Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002854" }, { "nct_id": "NCT06710847", "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms, Colorectal", "Solid Tumor", "Colon Cancer", "Rectal Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "GSK4418959", "type": "DRUG" }, { "name": "PD-1 inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2024-12-13", "completion_date": "2026-06-22", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-07-24T07:16:01.617Z", "location_count": 6, "location_summary": "Los Angeles, California • Denver, Colorado • Detroit, Michigan + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06710847" }, { "nct_id": "NCT06993844", "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Advanced Breast Cancer" ], "interventions": [ { "name": "ETX-636 dose escalation", "type": "DRUG" }, { "name": "ETX-636 dose escalation in combination with fulvestrant", "type": "DRUG" }, { "name": "ETX-636 dose expansion in combination with fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ensem Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 233, "start_date": "2025-06-10", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-24T07:16:01.617Z", "location_count": 10, "location_summary": "Newport Beach, California • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06993844" }, { "nct_id": "NCT03050268", "title": "Familial Investigations of Childhood Cancer Predisposition", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Leukemia", "Adenomatous Polyposis", "Adrenocortical Carcinoma", "AML", "BAP1 Tumor Predisposition Syndrome", "Carney Complex", "Choroid Plexus Carcinoma", "Constitutional Mismatch Repair Deficiency Syndrome", "Diamond-Blackfan Anemia", "DICER1 Syndrome", "Dyskeratosis Congenita", "Emberger Syndrome", "Familial Acute Myeloid Leukemia", "Familial Adenomatous Polyposis", "Fanconi Anemia", "Familial Cancer", "Familial Wilms Tumor", "Familial Neuroblastoma", "GIST", "Hereditary Breast and Ovarian Cancer", "Hereditary Paraganglioma-Pheochromocytoma Syndrome", "Hodgkin Lymphoma", "Juvenile Polyposis", "Li-Fraumeni Syndrome", "Lynch Syndrome", "MDS", "Melanoma Syndrome", "Multiple Endocrine Neoplasia Type 1", "Multiple Endocrine Neoplasia Type 2", "Neuroblastoma", "Neurofibromatosis Type 1", "Neurofibromatosis Type II", "Nevoid Basal Cell Carcinoma Syndrome", "Non Hodgkin Lymphoma", "Noonan Syndrome and Other Rasopathy", "Overgrowth Syndromes", "Pancreatic Cancer", "Peutz-Jeghers Syndrome", "Pheochromocytoma/Paraganglioma", "PTEN Hamartoma Tumor Syndrome", "Retinoblastoma", "Rhabdoid Tumor Predisposition Syndrome", "Rhabdomyosarcoma", "Rothmund-Thomson Syndrome", "Tuberous Sclerosis", "Von Hippel-Lindau Disease" ], "interventions": [], "intervention_types": [], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1500, "start_date": "2017-04-06", "completion_date": "2037-03-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-07-24T07:16:01.617Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03050268" }, { "nct_id": "NCT02142803", "title": "TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Glioblastoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Solid Neoplasm", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-05-20", "completion_date": "2026-10-16", "has_results": true, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-07-24T07:16:01.617Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Charlestown, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Charlestown", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02142803" }, { "nct_id": "NCT00964756", "title": "A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Ad5.SSTR/TK.RGD", "type": "GENETIC" }, { "name": "Ganciclovir (GCV)", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2009-08", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2013-02-13", "last_synced_at": "2026-07-24T07:16:01.617Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00964756" } ] }